Randomized controlled trial of screening for hepatocellular carcinoma

By Bo-heng Zhang, Bing-hui Yang, Zhao-You Tang. Journal of Cancer Research and Clinical Oncology, 2004

1,466 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/43eba703039824de1dcbb8cf8c3e4498dbfe2aa0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

In Hepatology

Citations in the corpus

Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma (2010, background): “[139] recruited 18,186 patients with chronic hepatitis due to HBV in China.”
Hepatocellular carcinoma: a review (2016, background): “Studies have found a survival benefit for early screening of patients for HCC.(51,52) Patients who are identified early consequently have multiple treatment options leading to”
Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis (2014, background): “Although surveillance among HBV patients is supported by a large randomized controlled trial, there is no similar level I evidence supporting this practice among patients with cirrhosis [7].”
Novel advancements in the management of hepatocellular carcinoma in 2008. (2008, background): “non-surveillance has shown benefits in terms of higher applicability of curative therapies in Chinese patients infected with HBV regardless of the presence of cirrhosis [7].”
Management of hepatocellular carcinoma: An update (2011, neutral): “The positive randomized control trial described earlier used a 6 month interval.(11) However, a retrospective study has reported that survival is no different in patients screened at 6 or 12 monthly intervals.”
Hepatocellular carcinoma: a global view (2010, methodology): “A randomized, controlled trial in China reported improved overall survival (a reduction in mortality of 37%) in the group of patients who underwent surveillance with ultrasonography and measurement of AFP levels every 6 months, compared with the group of patients assigned to no surveillance”
Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update (2017, background): “[389], in which biannual US and serum AFP measurement decreased mortality from HCC by 37%.”
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy (2023, positive): “%) and reduced HCC-related mortality (HR 0.63, 95% CI 0.41–0.98) 108 .”